Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
LUMOS PHARMA, INC. (NLNK)
|
Add to portfolio |
|
|
|
| Price: |
$7.33
| | Metrics |
| OS: |
7.94
|
M
| |
-73
|
% ROE
|
| Market cap: |
$58.2
|
M
| |
-245
|
% ROIC
|
|
Net cash:
|
$50.9
|
M
| |
$6.41
|
per share
|
|
EV:
|
$7.32
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($34.1)
|
M
| |
|
|
| EPS |
($3.82)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 1.5 | 0.2 | 0.2 | 0.0 | 12.5 | 28.7 | 35.8 | 68.5 |
| Revenue growth | 562.2% | 36.9% | | -100.0% | -56.6% | -19.7% | -47.8% | -60.3% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 1.5 | 0.2 | 0.2 | 0.0 | 12.5 | 28.7 | 35.8 | 68.5 |
| Gross margin | 100.0% | 100.0% | 100.0% | | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 17.9 | 16.2 | 9.2 | 5.7 | 45.7 | 69.9 | 93.3 | 71.4 |
| General and administrative | 15.7 | 15.3 | 17.3 | 4.1 | 29.2 | 31.7 | 33.2 | 30.7 |
| EBIT | -32.0 | -31.3 | -26.3 | -9.8 | -62.4 | -72.9 | -90.8 | -33.6 |
| EBIT margin | -2103.7% | -13629.1% | -15656.5% | | -500.5% | -253.8% | -253.7% | -49.1% |
| Pre-tax income | -31.1 | -31.1 | -19.6 | -9.7 | -60.6 | -72.5 | -90.5 | -33.6 |
| Income taxes | 0.0 | -0.6 | -14.0 | 0.0 | -7.0 | -0.6 | -5.4 | 6.7 |
| Tax rate | 0.0% | 2.0% | 71.2% | 0.0% | 11.5% | 0.8% | 5.9% | |
| Net income | -31.1 | -30.4 | -6.3 | -12.7 | -53.6 | -72.0 | -85.2 | -40.4 |
| Net margin | -2039.5% | -13230.4% | -3758.3% | | -429.7% | -250.6% | -238.1% | -58.9% |
| |
| Diluted EPS | ($3.71) | ($3.65) | ($0.93) | ($9.79) | ($1.44) | ($2.30) | ($2.94) | ($1.41) |
| Shares outstanding (diluted) | 8.4 | 8.3 | 6.8 | 1.3 | 37.2 | 31.3 | 29.0 | 28.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|